London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space

Nov 21, 2024

1 min read

Updated: Nov 27, 2024

Robert Barrow discusses MindMed's LSD based program that is going into phase 3 studies for generalized anxiety disorder and major depressive disorder and an earlier stage R(-)-MDMA program for autism spectrum disorder.

https://vimeo.com/1032102159?share=copy

Recent Posts

See All

At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

Earlier this month, Agilent agreed to acquire Philadelphia based Proscia, a provider of digital pathology software for clinical and life-sciences customers, for $240M up front and up to $30M more

Immuneering Co-Founder & CEO Ben Zeskind discusses the future of the third generation MEK inhibitor atebimetinib, which has shown promising data in first line pancreatic cancer

London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight